Abstract
Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Current Protein & Peptide Science
Title: Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases
Volume: 11 Issue: 8
Author(s): E. C.Y. Toh, N. L. Huq, S. G. Dashper and E. C. Reynolds
Affiliation:
Keywords: Cysteine proteases, cysteine protease inhibitors, therapeutics, infectious diseases, pathogen replication, immune response, evolutionary relationships, substrate specificity, nutrient acquisition, non-structural viral protein, Trypanosoma cruzi, Trypanosoma brucei, stefins, phytocystatins, factor aplha, interferon-γ-activated macrophages, nitric oxide, interleukin-10, β-immunoglobulin, proteolysis, BCPI
Abstract: Cysteine proteases are one of the largest groups of proteases and are involved in many important biological functions in all kingdoms of life. They are virulence factors of a range of eukaryotic, bacterial and viral pathogens and are involved in host invasion, pathogen replication and disruption of the host immune response. Their activity is regulated by a range of protease inhibitors. This review discusses the various families of cysteine protease inhibitors, their different modes of inhibition and their evolutionary relationships. These inhibitors as well as the recent discovery of propeptide and propeptide-like inhibitors provide insights into the structures that are important for particular inhibitory mechanisms, thus forming the foundation for the design of future therapeutics.
Export Options
About this article
Cite this article as:
C.Y. Toh E., L. Huq N., G. Dashper S. and C. Reynolds E., Cysteine Protease Inhibitors: from Evolutionary Relationships to Modern Chemotherapeutic Design for the Treatment of Infectious Diseases, Current Protein & Peptide Science 2010; 11 (8) . https://dx.doi.org/10.2174/138920310794557646
DOI https://dx.doi.org/10.2174/138920310794557646 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recognition of Lung Adenocarcinoma-specific Gene Pairs Based on Genetic Algorithm and Establishment of a Deep Learning Prediction Model
Combinatorial Chemistry & High Throughput Screening Cancer Stem Cells – Are Surface Markers Alone Sufficient?
Current Stem Cell Research & Therapy RAGE and RAGE Ligands in Cancer
Current Molecular Medicine Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Revising Skin Cancers by Means of Epigenetic Markers
Recent Patents on Biomarkers Decreased lncRNA SNHG16 Accelerates Oxidative Stress Induced Pathological Angiogenesis in Human Retinal Microvascular Endothelial Cells by Regulating miR-195/mfn2 Axis
Current Pharmaceutical Design Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Recent Developments in the Chemical Biology of Epothilones
Current Pharmaceutical Design Structure and Dynamics of Cardiotoxins
Current Protein & Peptide Science Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Chitosan Surface-Modified PLGA Nanoparticles: Preparation, Characterization, and Evaluation of their In Vitro Drug-Release Behaviors and Cytotoxicities
Current Nanoscience Role of Copper in Angiogenesis and Its Medicinal Implications
Current Medicinal Chemistry Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2
Current Neurovascular Research Cell Hierarchy, Metabolic Flexibility and Systems Approaches to Cancer Treatment
Current Pharmaceutical Biotechnology Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Current Pharmaceutical Design Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design Antibody Gene Therapy: Getting Closer to Clinical Application?
Current Gene Therapy